Prostate cancer accounts for 3.8% of total cancer-related deaths worldwide. The combination of docetaxel and androgen deprivation therapy is useful in the management of the disease, but unfortunately, prostate cancer cells become resistant to docetaxel over time.
Shenzhen Chipscreen Biosciences Co. Ltd. has submitted an IND application for CS-231295 tablets for the treatment of tumors, and the application has been accepted by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA).
Poseida Therapeutics Inc. has announced the nomination of a new development candidate under its collaboration with F. Hoffmann-La Roche Ltd., triggering a milestone payment from Roche to Poseida.
Shine Technologies LLC and WARF Therapeutics, a drug discovery program by the Wisconsin Alumni Research Foundation (WARF), have announced promising preclinical research results from collaborative efforts with the advanced radiotheranostics lab at the University of Wisconsin-Madison.
Chimeric antigen receptor (CAR) T-cell therapies (CAR T) have proven effective in several hematological cancers and are advancing across the pipelines of other types of tumors with limited efficacy, such as in the more complex environment of solid tumors.
During an Innovation Ignited webinar sponsored by Johnson & Johnson, experts talked about how precision medicine has helped advance the field of oncology and how those lessons can be applied to immunology.
The BioWorld Biopharmaceutical Index (BBI) climbed 16.92% in the first three quarters of the year, bolstered by second quarter (Q2) results despite disappointing clinical news from several players. The BBI maintained its lead over both the Nasdaq Biotechnology Index, which increased by 9.09%, and the Dow Jones Industrial Average, which saw a 12.31% rise.
Clarity Pharmaceuticals Ltd. will begin early next year its pivotal phase III trial for its copper-based radiopharmaceutical, 64Cu-SAR-bisPSMA, for diagnosing prostate cancer in patients with biochemical recurrence following positive U.S. FDA feedback.
RSS
